TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23085706

Group type: EXPERIMENTAL
Intervention: Ultrasonography-guided injection
Number of subjects: 47

Group type: COMPARATOR
Intervention: Manual needle placement
Number of subjects: 47

Group type: COMPARATOR
Intervention: Electrical stimulation
Number of subjects: 47
Study: 20801856

Group type: EXPERIMENTAL
Intervention: Cryoablation
Number of subjects: 124

Group type: COMPARATOR
Intervention: Radiofrequency ablation (RFA)
Number of subjects: 124
Study: 18672254

Group type: EXPERIMENTAL
Intervention: Infliximab (5 mg/kg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Second IVIG infusion (2 g/kg)
Number of subjects: 24
Study: 16164708

Group type: EXPERIMENTAL
Intervention: Alefacept plus UVB treatment (6-week and 12-week)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Alefacept monotherapy
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Combination therapy (alefacept/UVB)
Number of subjects: 60
Study: 12858653

Group type: EXPERIMENTAL
Intervention: Memantine 10 mg twice daily for up to 28 weeks
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Memantine 10 mg twice daily
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 10371538

Group type: EXPERIMENTAL
Intervention: Topiramate (titrated to approximately 6 mg/kg/d)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Topiramate
Number of subjects: 98

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98
Study: 8898424

Group type: EXPERIMENTAL
Intervention: Recombinant interferon-alpha 2a therapy for 26 weeks
Number of subjects: 97
Study: 2060541

Group type: EXPERIMENTAL
Intervention: Glipizide 0.5 mg
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Glipizide 1.0 mg
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Glipizide 2.5 mg
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 6295596

Group type: EXPERIMENTAL
Intervention: VP-16 (180 mg/m2 on 3 consecutive days at 2 weekly intervals)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Adriamycin
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: VP-16
Number of subjects: 35
Study: 31859732

Group type: EXPERIMENTAL
Intervention: M-CHAT-R/F
Number of subjects: 120
Study: 29398432

Group type: EXPERIMENTAL
Intervention: Dual-phase cone-beam computed tomography (DP-CBCT)
Number of subjects: 42
Study: 27180994

Group type: EXPERIMENTAL
Intervention: Plain lignocaine
Number of subjects: 50

Group type: COMPARATOR
Intervention: Lignocaine with vasoconstrictor
Number of subjects: 50
Study: 24532111

Group type: EXPERIMENTAL
Intervention: Multi-thermocouple probe
Number of subjects: 100

Group type: COMPARATOR
Intervention: Deflectable temperature probe
Number of subjects: 100
Study: 22394471

Group type: EXPERIMENTAL
Intervention: Org 25935 (4 mg)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Org 25935 (12 mg)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 20079620

Group type: EXPERIMENTAL
Intervention: Injecting methamphetamine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Injecting heroin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Injecting drugs (general)
Number of subjects: 0
Study: 17630221

Group type: EXPERIMENTAL
Intervention: Cigarette pack with graphic image warning label
Number of subjects: 89

Group type: COMPARATOR
Intervention: Cigarette pack with text-only warning label
Number of subjects: 89
Study: 16277632

Group type: EXPERIMENTAL
Intervention: 2 mg rapid-release nicotine gum (RRNG)
Number of subjects: 319

Group type: COMPARATOR
Intervention: 2 mg nicotine polacrilex gum (NPG)
Number of subjects: 319
Study: 12804864

Group type: EXPERIMENTAL
Intervention: Ventrogluteal injection of DTPw vaccine
Number of subjects: 849

Group type: EXPERIMENTAL
Intervention: Ventrogluteal injection of DTPa vaccine
Number of subjects: 849

Group type: EXPERIMENTAL
Intervention: Ventrogluteal injection of HibTITER vaccine
Number of subjects: 849

Group type: EXPERIMENTAL
Intervention: Ventrogluteal injection
Number of subjects: 849

Group type: COMPARATOR
Intervention: Anterolateral thigh injection
Number of subjects: 849
Study: 10605191

Group type: EXPERIMENTAL
Intervention: Triple combinations including two nucleoside analogues and a potent protease inhibitor
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Indinavir in association with AZT plus 3TC
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Protease inhibitors and triple therapy
Number of subjects: 0
Study: 8947337

Group type: EXPERIMENTAL
Intervention: Semidepot perennial grass-pollen extract for 4 years
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Nasal allergen challenges after 4 years' immunotherapy
Number of subjects: 17
Study: 1836098

Group type: EXPERIMENTAL
Intervention: Captopril 50 mg twice daily
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 6755307

Group type: COMPARATOR
Intervention: Basic therapy + calcitonin
Number of subjects: 45

Group type: COMPARATOR
Intervention: Basic therapy + calcifediol
Number of subjects: 45

Group type: COMPARATOR
Intervention: Basic therapy only
Number of subjects: 45
Study: 30791079

Group type: EXPERIMENTAL
Intervention: Heated water-based exercise (HEx)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Land-based exercise (LEx)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Non-exercise control (CON)
Number of subjects: 15
Study: 29069568

Group type: EXPERIMENTAL
Intervention: Surgery group (n=57)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Medical-therapy group (n=59)
Number of subjects: 116
Study: 27405353

Group type: EXPERIMENTAL
Intervention: Cervical pessary
Number of subjects: 200

Group type: COMPARATOR
Intervention: No intervention (usual care)
Number of subjects: 200
Study: 24382677

Group type: EXPERIMENTAL
Intervention: Bereaved informal caregivers of palliative care patients
Number of subjects: 84

Group type: COMPARATOR
Intervention: General population (n=977)
Number of subjects: 84
Study: 21971755

Group type: EXPERIMENTAL
Intervention: Electrostimulation treatment protocol (30 sessions starting four days post-operation)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control group (exercise alone)
Number of subjects: 29
Study: 18990715

Group type: EXPERIMENTAL
Intervention: Symptomatic remission
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Functional remission
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Both symptomatic and functional remission (recovery)
Number of subjects: 125
Study: 17499892

Group type: EXPERIMENTAL
Intervention: Tube feeding
Number of subjects: 81
Study: 15367192

Group type: EXPERIMENTAL
Intervention: Essential oil mouthrinse (Listerine Antiseptic)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: 0.12% chlorhexidine mouthrinse (Peridex)
Number of subjects: 108

Group type: COMPARATOR
Intervention: 5% hydroalcohol negative control
Number of subjects: 108
Study: 16604577

Group type: EXPERIMENTAL
Intervention: Monitor kit version 1.0
Number of subjects: 634

Group type: EXPERIMENTAL
Intervention: EDTA tubes
Number of subjects: 634

Group type: COMPARATOR
Intervention: Monitor kit version 1.5
Number of subjects: 634
Study: 10853696

Group type: EXPERIMENTAL
Intervention: Acute submaximal exercise with NO inhalation (mask)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Acute submaximal exercise without NO inhalation (no mask)
Number of subjects: 7
Study: 8644685

Group type: EXPERIMENTAL
Intervention: Choline supplementation (13.5 mmol/d) plus pantothenate (1.4 mmol/d)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Choline supplementation (0.20 mmol/kg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pantothenate supplementation (0.02 mmol/kg)
Number of subjects: 0
Study: 1325076

Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin CY 216 (Fraxiparine) in a fixed dose
Number of subjects: 149

Group type: COMPARATOR
Intervention: Unfractionated heparin (UFH) in doses adjusted according to the activated partial thromboplastin time
Number of subjects: 149
Study: 6465619

Group type: EXPERIMENTAL
Intervention: Pentoxifylline (1200 mg/day, Trental 400 tds.)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Acetylsalicylic acid and dipyridamole (1050 mg + 150 mg/day)
Number of subjects: 97
Study: 31839158

Group type: EXPERIMENTAL
Intervention: Low-dose tamoxifen (5 mg/day)
Number of subjects: 500

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 500
Study: 29329305

Group type: EXPERIMENTAL
Intervention: TDF monotherapy (n = 111)
Number of subjects: 169

Group type: COMPARATOR
Intervention: LAM+ADV combination therapy (n = 58)
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: TDF monotherapy (n = 111) with cirrhosis
Number of subjects: 169
Study: 26823540

Group type: EXPERIMENTAL
Intervention: Monovalent rotavirus vaccine (2 doses)
Number of subjects: 1393

Group type: EXPERIMENTAL
Intervention: Mixed vaccine schedules (3 doses)
Number of subjects: 1393

Group type: COMPARATOR
Intervention: Single vaccine reference groups (2 doses)
Number of subjects: 1393
Study: 25042313

Group type: EXPERIMENTAL
Intervention: New Formula
Number of subjects: 18

Group type: COMPARATOR
Intervention: Old Formula
Number of subjects: 18
Study: 22285609

Group type: EXPERIMENTAL
Intervention: multicomponent cognitive‐behavioral therapy (CBT)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: multicomponent cognitive‐behavioral therapy (CBT) with hypnosis
Number of subjects: 93

Group type: COMPARATOR
Intervention: standard care (pharmacological treatment)
Number of subjects: 93
Study: 19283745

Group type: EXPERIMENTAL
Intervention: EVLT with concomitant ambulatory phlebectomies (EVLTAP)
Number of subjects: 50

Group type: COMPARATOR
Intervention: EVLT alone
Number of subjects: 50
Study: 17202433

Group type: EXPERIMENTAL
Intervention: Individualized dietary modification + recombinant human growth hormone (GH) (0.1 mg/kg daily x 21 days, then 3 times/week)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Individualized dietary modification + placebo
Number of subjects: 24
Study: 15771782

Group type: EXPERIMENTAL
Intervention: Simvastatin 40 mg daily
Number of subjects: 20536

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20536
Study: 12475853

Group type: EXPERIMENTAL
Intervention: Decelerating waveform
Number of subjects: 54

Group type: COMPARATOR
Intervention: Constant square waveform
Number of subjects: 54

Group type: COMPARATOR
Intervention: Sine waveform
Number of subjects: 54
Study: 9791525

Group type: EXPERIMENTAL
Intervention: Intensified education through a booklet about amblyopia and its treatment.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ordinary information provided at two departments of paediatric ophthalmology.
Number of subjects: 0
Study: 7702027

Group type: EXPERIMENTAL
Intervention: 4 g fish-oil concentrate/d (approximately 3.4 g eicosapentaenoic and docosahexaenoic acids/d)
Number of subjects: 511

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 511

Group type: EXPERIMENTAL
Intervention: 4 g fish-oil concentrate/d
Number of subjects: 511
Study: 31596518

Group type: EXPERIMENTAL
Intervention: Plasma IL‐18 concentrations measured at admission, discharge, 1 month, and 6 months
Number of subjects: 16636

Group type: EXPERIMENTAL
Intervention: Baseline IL‐18 levels
Number of subjects: 16636

Group type: EXPERIMENTAL
Intervention: Cox regression models
Number of subjects: 16636

Group type: EXPERIMENTAL
Intervention: Adjustment for clinical risk factors and biomarkers (cTnT‐hs, NT‐proBNP, cystatin C, CRP‐hs, and GDF‐15)
Number of subjects: 16636

Group type: EXPERIMENTAL
Intervention: IL‐18 concentrations
Number of subjects: 16636

Group type: EXPERIMENTAL
Intervention: No associations with sMI
Number of subjects: 16636
Study: 27530310

Group type: EXPERIMENTAL
Intervention: IVIG 1 g/kg/day for two consecutive days
Number of subjects: 24

Group type: COMPARATOR
Intervention: PLEX 1-L plasma exchange five times with 5% albumin replacement fluid, every other day, 10-30 days before the procedure
Number of subjects: 24
Study: 25447038

Group type: EXPERIMENTAL
Intervention: 15 min in-situ IHCA training sessions every two months (2M)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 15 min in-situ IHCA training sessions every three months (3M)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 15 min in-situ IHCA training sessions every six months (6M)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard AHA training (C)
Number of subjects: 0
Study: 23576043

Group type: EXPERIMENTAL
Intervention: Chronic red wine (RW) consumption
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Acute red wine (RW) intake with fat overload
Number of subjects: 10
Study: 21216855

Group type: EXPERIMENTAL
Intervention: Web-based CBT
Number of subjects: 255
Study: 19514093

Group type: EXPERIMENTAL
Intervention: STN-DBS
Number of subjects: 65
Study: 16205904

Group type: EXPERIMENTAL
Intervention: Pregabalin fixed dose treatment
Number of subjects: 338

Group type: EXPERIMENTAL
Intervention: Pregabalin flexible dose treatment
Number of subjects: 338

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 338
Study: 15456623

Group type: EXPERIMENTAL
Intervention: Immunotherapy administered in the initiation phase according to a cluster schedule of eight doses injected on four visits.
Number of subjects: 191

Group type: COMPARATOR
Intervention: Control group (no immunotherapy).
Number of subjects: 191
Study: 11287014

Group type: EXPERIMENTAL
Intervention: Intrauterine insemination (IUI)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Intracervical insemination (ICI)
Number of subjects: 62
Study: 9237962

Group type: COMPARATOR
Intervention: Olestra 0 g/d
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Olestra 8 g/d
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Olestra 20 g/d
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Olestra 32 g/d
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Addition of 2.1 mg d‐alpha‐tocopheryl acetate and 0.06 microg ergocalciferol per gram of olestra
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Olestra (all doses)
Number of subjects: 102
Study: 8233263

Group type: EXPERIMENTAL
Intervention: Ear, hand, and foot reflexology treatment
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo reflexology
Number of subjects: 35
Study: 3317354

Group type: EXPERIMENTAL
Intervention: Recombinant yeast‐derived hepatitis B vaccine (3 doses of 40 micrograms) administered at 0, 1, 2 months
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Recombinant yeast‐derived hepatitis B vaccine (3 doses of 40 micrograms) administered at 0, 1, 6 months
Number of subjects: 80
Study: 31378406

Group type: EXPERIMENTAL
Intervention: Bilateral antegrade cerebral perfusion
Number of subjects: 184

Group type: COMPARATOR
Intervention: Unilateral antegrade cerebral perfusion
Number of subjects: 184
Study: 29907128

Group type: EXPERIMENTAL
Intervention: Strengthening Families Programme 10-14 (SFP 10-14 or 'Familias Fuertes') alongside services-as-usual
Number of subjects: 840

Group type: COMPARATOR
Intervention: Services-as-usual
Number of subjects: 840
Study: 27225988

Group type: EXPERIMENTAL
Intervention: Stenting
Number of subjects: 931

Group type: COMPARATOR
Intervention: Medical therapy only (no stenting)
Number of subjects: 931

Group type: COMPARATOR
Intervention: Overall CKD outcomes
Number of subjects: 931

Group type: COMPARATOR
Intervention: Overall cardiovascular disease outcomes
Number of subjects: 931
Study: 23996068

Group type: EXPERIMENTAL
Intervention: BPTB reconstruction with synthetic degradable augmentation device
Number of subjects: 201

Group type: COMPARATOR
Intervention: BPTB reconstruction without augmentation
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Both groups (with and without augmentation)
Number of subjects: 201
Study: 23451449

Group type: EXPERIMENTAL
Intervention: Plygersic gel (4% ginger and plai extract)
Number of subjects: 100

Group type: COMPARATOR
Intervention: 1% Diclofenac gel
Number of subjects: 100
Study: 19902277

Group type: EXPERIMENTAL
Intervention: Plasma disc decompression (PDD)
Number of subjects: 115

Group type: COMPARATOR
Intervention: Conservative care (CC)
Number of subjects: 115
Study: 18318721

Group type: EXPERIMENTAL
Intervention: Intense Pulsed Light (IPL) - 560-nm filter, 30 J/cm², 2.4/4.0-ms pulse with 10-ms delay, three treatments spaced 1 month apart
Number of subjects: 10

Group type: COMPARATOR
Intervention: Er:YAG laser - 3.8 J/cm², 30% pattern overlap, 0% interpulse overlap, 15 microm per pass, three treatments spaced 1 month apart
Number of subjects: 10
Study: 15833457

Group type: EXPERIMENTAL
Intervention: Metal-on-metal cemented resurfacing hip replacement
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cemented total hip replacement
Number of subjects: 0
Study: 12744873

Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation
Number of subjects: 395

Group type: COMPARATOR
Intervention: Unsupplemented children (Control)
Number of subjects: 395
Study: 10482323

Group type: EXPERIMENTAL
Intervention: Three hourly nebulized salbutamol
Number of subjects: 63

Group type: COMPARATOR
Intervention: Four hourly nebulized salbutamol
Number of subjects: 63
Study: 8621298

Group type: EXPERIMENTAL
Intervention: Half-beam with a custom block (HB+CB)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Half-beam using asymmetric collimator jaw (HB/AJ)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Half-beam using asymmetric collimator jaw with custom block (H/AJ+CB)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Isocentric technique with nondivergent posterior borders (JCRT technique)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Asymmetric jaw with no medial wedge
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Medial wedge (used in all techniques)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Asymmetric half-beam technique
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cerrobend half-beam blocking
Number of subjects: 0
Study: 1751998

Group type: EXPERIMENTAL
Intervention: Metoclopramide 0.15 mg.kg‐1
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 7141758

Group type: EXPERIMENTAL
Intervention: Fortimicin A 2.5 mg/kg
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Fortimicin A 5.0 mg/kg
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Fortimicin A 7.5 mg/kg
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Overall mean beta-phase half-life
Number of subjects: 17
Study: 30777113

Group type: EXPERIMENTAL
Intervention: Cellie Coping Kit for Children with Injury intervention
Number of subjects: 80

Group type: COMPARATOR
Intervention: Waitlist group (control)
Number of subjects: 80
Study: 30030322

Group type: EXPERIMENTAL
Intervention: MoodGYM plus Check Your Drinking (CYD)
Number of subjects: 986

Group type: COMPARATOR
Intervention: MoodGYM
Number of subjects: 986
Study: 26978668

Group type: EXPERIMENTAL
Intervention: Pre-quit reduction in anxiety sensitivity
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Anxiety sensitivity class membership
Number of subjects: 195
Study: 25256892

Group type: EXPERIMENTAL
Intervention: Whole body hyperthermia treatment at 38.7-39°C for 60 minutes
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Whole body hyperthermia treatment
Number of subjects: 16
Study: 21362636

Group type: EXPERIMENTAL
Intervention: Gut-directed hypnotherapy (HYP)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Active attention control (CON)
Number of subjects: 36
Study: 20093825

Group type: EXPERIMENTAL
Intervention: Renal progenitor/stem cell therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cytopheretic membranes
Number of subjects: 0

Group type: COMPARATOR
Intervention: Smart immunomodulatory membrane
Number of subjects: 0
Study: 18059593

Group type: EXPERIMENTAL
Intervention: Carbohydrate supplementation (1 g.kg(‐1).d(‐1))
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Glutamine supplementation (70 mg.kg(‐1).d(‐1))
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Combination of carbohydrate and glutamine supplementation
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control (no supplementation)
Number of subjects: 15
Study: 16026373

Group type: EXPERIMENTAL
Intervention: Close glycaemic control intervention
Number of subjects: 1

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 1
Study: 11843508

Group type: EXPERIMENTAL
Intervention: Homograft (group H)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Medtronic Freestyle xenograft (group F)
Number of subjects: 15
Study: 10028374

Group type: EXPERIMENTAL
Intervention: New slow release tablet formulation (Pindac) 12.5 mg every 12 h for 7 days
Number of subjects: 18

Group type: COMPARATOR
Intervention: Standard slow release capsule formulation 12.5 mg every 12 h for 7 days
Number of subjects: 18
Study: 7672764

Group type: COMPARATOR
Intervention: Liver resection (Group A)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Liver resection combined with post-operative locoregional immunotherapy + chemotherapy (Group B)
Number of subjects: 40
Study: 2285086

Group type: EXPERIMENTAL
Intervention: Primary repair
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Bone-patellar tendon-bone augmentation
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Kennedy Ligament Augmentation Device
Number of subjects: 150
Study: 7178370

Group type: EXPERIMENTAL
Intervention: Desimipramine (DMI)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Diazepam (10 mg i.v.)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Metaclazepam (10 mg p.o. and 30 mg p.o.)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 30143879

Group type: EXPERIMENTAL
Intervention: Very thin-strut biodegradable polymer drug-eluting stents (BP-DES)
Number of subjects: 1009

Group type: COMPARATOR
Intervention: Thin-strut durable polymer drug-eluting stents (DP-DES)
Number of subjects: 1009
Study: 26773296

Group type: EXPERIMENTAL
Intervention: Food insufficiency (measured by days of hunger in the past week)
Number of subjects: 1238

Group type: EXPERIMENTAL
Intervention: Food insufficiency among women with low levels of instrumental support
Number of subjects: 1238

Group type: EXPERIMENTAL
Intervention: Food insufficiency (quantile regression analysis)
Number of subjects: 1238

Group type: EXPERIMENTAL
Intervention: Fixed-effects regression models and fixed-effects quantile regression models
Number of subjects: 1238
Study: 25899926

Group type: EXPERIMENTAL
Intervention: 1g of acetaminophen twice daily for 12 weeks
Number of subjects: 94

Group type: COMPARATOR
Intervention: Placebo twice daily for 12 weeks
Number of subjects: 94
Study: 23113934

Group type: EXPERIMENTAL
Intervention: Interval training (IT) 3 times a week for 7 weeks
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Interval training (IT)
Number of subjects: 15
Study: 20004370

Group type: EXPERIMENTAL
Intervention: Pure genistein (n=21)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo (n=17)
Number of subjects: 38